LinMeiMD_onc's profile picture. Genitourinary Oncology, Penn Medicine, Abramson Cancer Center. Interested in rare GU malignacies, cancer immunology and brain metastasis. Tweets are my own view

Lin Mei

@LinMeiMD_onc

Genitourinary Oncology, Penn Medicine, Abramson Cancer Center. Interested in rare GU malignacies, cancer immunology and brain metastasis. Tweets are my own view

Appreciated all the staffs. It is a lot of effort.

The Oncology Evaluation Center helps cancer patients with complications that arise in between scheduled treatments—easing their care and their anxiety. Open 24/7, it’s a place where patients can go for help with side effects, bypassing the emergency room. spr.ly/60157OiBU

PennMedicine's tweet image. The Oncology Evaluation Center helps cancer patients with complications that arise in between scheduled treatments—easing their care and their anxiety. Open 24/7, it’s a place where patients can go for help with side effects, bypassing the emergency room.  spr.ly/60157OiBU


Lin Mei さんがリポスト

Radiation oncologists are trained to deliver safe, high-precision radiotherapy as part of a #cancer care team. We follow the best available evidence & develop customized, cost-effective plans. Science guides our treatments, but humanity guides our practice. 1/2

In the News: ASTRO marks President Biden’s treatment milestone with ASTRO President Neha Vapiwala, MD leading the treatment team. @NehaVapiwala @SameerKeoleMD @PennMedicine @JoeBiden ow.ly/yCUo50XgSQh

ASTRO_org's tweet image. In the News: ASTRO marks President Biden’s treatment milestone with ASTRO President Neha Vapiwala, MD leading the treatment team.  @NehaVapiwala @SameerKeoleMD @PennMedicine @JoeBiden

ow.ly/yCUo50XgSQh


Wow. Penn Medicine is the best. Appreciate @NehaVapiwala

Congratulations to President @JoeBiden for finishing RT under the care of @ASTRO_org President @NehaVapiwala @PennMedicine #radonc

SameerKeoleMD's tweet image. Congratulations to President @JoeBiden for finishing RT under the care of @ASTRO_org President @NehaVapiwala 

@PennMedicine #radonc
SameerKeoleMD's tweet image. Congratulations to President @JoeBiden for finishing RT under the care of @ASTRO_org President @NehaVapiwala 

@PennMedicine #radonc


Lin Mei さんがリポスト

Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics authors.elsevier.com/a/1ljMf5EIIgTS…

ChadTangMD's tweet image. Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics 

authors.elsevier.com/a/1ljMf5EIIgTS…

I will change again.

The +ve periopertive EVP trial for OS in cis ineligible MIBC may open a new area. Especially if its like EVP in M1 disease. 3 more trials in this area are awaited which test 1) EVP vs cisplatin (NIAGARA population), 2) EV/PD1/CTLA4 vs surgery 3) treatment based on ctDNA status.

tompowles1's tweet image. The +ve periopertive EVP trial for OS in cis ineligible MIBC may open a new area. Especially if its like EVP in M1  disease. 3 more trials in this area are awaited which test 1) EVP vs cisplatin (NIAGARA population), 2) EV/PD1/CTLA4 vs surgery 3) treatment based on ctDNA status.
tompowles1's tweet image. The +ve periopertive EVP trial for OS in cis ineligible MIBC may open a new area. Especially if its like EVP in M1  disease. 3 more trials in this area are awaited which test 1) EVP vs cisplatin (NIAGARA population), 2) EV/PD1/CTLA4 vs surgery 3) treatment based on ctDNA status.
tompowles1's tweet image. The +ve periopertive EVP trial for OS in cis ineligible MIBC may open a new area. Especially if its like EVP in M1  disease. 3 more trials in this area are awaited which test 1) EVP vs cisplatin (NIAGARA population), 2) EV/PD1/CTLA4 vs surgery 3) treatment based on ctDNA status.


Lin Mei さんがリポスト
DrYukselUrun's tweet image. A mind-opener review on muscle-invasive bladder cancer. Must-read for GU oncologist.
#BladderCancer #Oncology #Immunotherapy
@MattGalsky  @l_ballas @UroDocAsh @ASCO @JCO_ASCO @WorldBladderCan @OncoAlert @OncBrothers @Uromigos @urologysummit 
doi.org/10.1200/JCO-25…
DrYukselUrun's tweet image. A mind-opener review on muscle-invasive bladder cancer. Must-read for GU oncologist.
#BladderCancer #Oncology #Immunotherapy
@MattGalsky  @l_ballas @UroDocAsh @ASCO @JCO_ASCO @WorldBladderCan @OncoAlert @OncBrothers @Uromigos @urologysummit 
doi.org/10.1200/JCO-25…
DrYukselUrun's tweet image. A mind-opener review on muscle-invasive bladder cancer. Must-read for GU oncologist.
#BladderCancer #Oncology #Immunotherapy
@MattGalsky  @l_ballas @UroDocAsh @ASCO @JCO_ASCO @WorldBladderCan @OncoAlert @OncBrothers @Uromigos @urologysummit 
doi.org/10.1200/JCO-25…
DrYukselUrun's tweet image. A mind-opener review on muscle-invasive bladder cancer. Must-read for GU oncologist.
#BladderCancer #Oncology #Immunotherapy
@MattGalsky  @l_ballas @UroDocAsh @ASCO @JCO_ASCO @WorldBladderCan @OncoAlert @OncBrothers @Uromigos @urologysummit 
doi.org/10.1200/JCO-25…

Our study regarding the race, sex and age disparity in metastatic bladder cancer. Actually, female sex and older patients didn't show worse outcomes than the comparators. clinical-genitourinary-cancer.com/article/S1558-…


Congratulations and thanks for the effort from everybody!


Lin Mei さんがリポスト

Terrific presentation by #VivekNarayan Ab#4507 @ASCO #ASCO25 👉5-yr f/u of Ph2 LITESPARK-004👉Belzutifan shows durable activity and manageable toxicity in VHL-associated neoplasms (ORR 70% in RCC) #kidneycancer👇@OncoAlert @urotoday @kidneycancer

neerajaiims's tweet image. Terrific presentation by #VivekNarayan Ab#4507 @ASCO #ASCO25 👉5-yr f/u of Ph2 LITESPARK-004👉Belzutifan shows durable activity and manageable toxicity in VHL-associated neoplasms (ORR 70% in RCC) #kidneycancer👇@OncoAlert @urotoday @kidneycancer
neerajaiims's tweet image. Terrific presentation by #VivekNarayan Ab#4507 @ASCO #ASCO25 👉5-yr f/u of Ph2 LITESPARK-004👉Belzutifan shows durable activity and manageable toxicity in VHL-associated neoplasms (ORR 70% in RCC) #kidneycancer👇@OncoAlert @urotoday @kidneycancer
neerajaiims's tweet image. Terrific presentation by #VivekNarayan Ab#4507 @ASCO #ASCO25 👉5-yr f/u of Ph2 LITESPARK-004👉Belzutifan shows durable activity and manageable toxicity in VHL-associated neoplasms (ORR 70% in RCC) #kidneycancer👇@OncoAlert @urotoday @kidneycancer
neerajaiims's tweet image. Terrific presentation by #VivekNarayan Ab#4507 @ASCO #ASCO25 👉5-yr f/u of Ph2 LITESPARK-004👉Belzutifan shows durable activity and manageable toxicity in VHL-associated neoplasms (ORR 70% in RCC) #kidneycancer👇@OncoAlert @urotoday @kidneycancer

Congratulations Vivek! @Ron_cology @PennCancer

Vivek Narayan, MD, MS receives the 2025 Pearl and Phil Innovation Research Award for his work impacting male BRCA mutation carriers as a prostate cancer clinical investigator improving treatments for BRCA-related prostate cancer and overcoming treatment resistance. @PennCancer

BasserBRCA's tweet image. Vivek Narayan, MD, MS receives the 2025 Pearl and Phil Innovation Research Award for his work impacting male BRCA mutation carriers as a prostate cancer clinical investigator improving treatments for BRCA-related prostate cancer and overcoming treatment resistance. @PennCancer


One of my patient was in this trial. Amazing work from Penn. @PennCancer Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | New England Journal of Medicine nejm.org/doi/full/10.10…


Lin Mei さんがリポスト

A @PennMedicine pilot study led by Ronac Mamtani, MD (@Ron_cology), demonstrated that text message check-ins, instead of in-person visits, could save cancer patients more than 60 minutes per appointment. @HemOncToday spr.ly/60122Rwj0


Specially interested to see 1 and 2.

Bladder cancer highlights #ASCOGU25 1) outcomes of pCR patients for gem/cis/durvalumab (NIAGARA) 2) neoadjuvant gem/cis/durvalumab in upper tract disease 3) Neoadjuvant DV/PD1 in MIBC (pCR >50%?) 3) Longer OS follow up for EVP 4) Data on DDXD and new FGFR3i in pretreated patients



Lin Mei さんがリポスト

Just in @CACancerJournal 👉Comprehensive review of efficacy & safety data of PARP inhibitors across cancer types #prostatecancer, #ovariancancer, #breastcancer & others 👉Open access weblink👉 bit.ly/42apBgy @chadihc98 @Huntsman_GU  @OncoAlert @urotoday @PCF_Science

neerajaiims's tweet image. Just in @CACancerJournal 👉Comprehensive review of efficacy & safety data of PARP inhibitors across cancer types #prostatecancer, #ovariancancer, #breastcancer & others 👉Open access weblink👉
bit.ly/42apBgy @chadihc98 @Huntsman_GU  @OncoAlert @urotoday @PCF_Science
neerajaiims's tweet image. Just in @CACancerJournal 👉Comprehensive review of efficacy & safety data of PARP inhibitors across cancer types #prostatecancer, #ovariancancer, #breastcancer & others 👉Open access weblink👉
bit.ly/42apBgy @chadihc98 @Huntsman_GU  @OncoAlert @urotoday @PCF_Science
neerajaiims's tweet image. Just in @CACancerJournal 👉Comprehensive review of efficacy & safety data of PARP inhibitors across cancer types #prostatecancer, #ovariancancer, #breastcancer & others 👉Open access weblink👉
bit.ly/42apBgy @chadihc98 @Huntsman_GU  @OncoAlert @urotoday @PCF_Science
neerajaiims's tweet image. Just in @CACancerJournal 👉Comprehensive review of efficacy & safety data of PARP inhibitors across cancer types #prostatecancer, #ovariancancer, #breastcancer & others 👉Open access weblink👉
bit.ly/42apBgy @chadihc98 @Huntsman_GU  @OncoAlert @urotoday @PCF_Science

Lin Mei さんがリポスト

From @asco @JCOOP_ASCO 71% of US counties either lack an oncologist (20%) or lack an open cancer trials (50%). Meanwhile trends show declining % of oncologists in rural communities. Pair this with @wsj piece on community oncs being overwhelmed by clinical advances.

DrHBurstein's tweet image. From @asco @JCOOP_ASCO 
71% of US counties either lack an oncologist  (20%) or lack an open cancer trials (50%).  Meanwhile trends show declining % of oncologists in rural communities.  
Pair this with @wsj piece on community oncs being overwhelmed by clinical advances.

Legendary

Mil gracias a todos Many thanks to all Merci beaucoup à tous Grazie mille à tutti 谢谢大家 شكرا لكم جميعا תודה לכולכם Obrigado a todos Vielen Dank euch allen Tack alla Хвала свима Gràcies a tots



Thanks for our resident @ABarsouk hard work and dedication. Appreciate @Ron_cology support for your review article. We have found women's bladder cancer still has inferior outcomes even in the modern treatment era.

Meta-Analysis of Age, Sex, and Race Disparities in the Era of Contemporary Urothelial Carcinoma Treatment mdpi.com/2977898 #mdpicancers via @Cancers_MDPI



Meta-Analysis of Age, Sex, and Race Disparities in the Era of Contemporary Urothelial Carcinoma Treatment mdpi.com/2977898 #mdpicancers via @Cancers_MDPI


Excellent review

From @JAMA_current: Renal cell carcinoma (RCC) is a common cancer, with an estimated 434 840 incident cases worldwide in 2022. This review summarizes the epidemiology, clinical presentation, pathophysiology, and management of RCC. ja.ma/4ezLtVm

JAMAOnc's tweet image. From @JAMA_current: Renal cell carcinoma (RCC) is a common cancer, with an estimated 434 840 incident cases worldwide in 2022. This review summarizes the epidemiology, clinical presentation, pathophysiology, and management of RCC. ja.ma/4ezLtVm


Loading...

Something went wrong.


Something went wrong.